Engineering the pipeline from bench to batch.
Cell and gene therapies are scaling from niche treatments to production platforms, AI is compressing drug development timelines from years to months, and a looming patent cliff is forcing every biopharma and medtech company to rethink how fast it can move. Arrow Ways embeds the process, quality, and data engineering talent — and the strategic consulting — to help life sciences organizations scale toward 2027 and beyond without breaking GMP compliance in the process.
to Patent Cliff by 2028
Market Through 2034
Timeline in Recent Case Study
The pipeline that gets built now determines who survives the patent cliff.
Four forces — the loss-of-exclusivity cliff, cell and gene therapy scale-up, AI-compressed R&D, and data fragmentation — are converging to reset how biopharma, biotech, and medtech companies compete through 2027 and beyond.
The patent cliff is forcing a pipeline reckoning.
More than half of biopharma revenue is tied to intellectual property set to lose exclusivity by 2027, putting roughly $300 billion in branded pharma revenue at risk this decade and driving urgent M&A and internal R&D investment to replenish pipelines.
Cell and gene therapy is moving from lab to line.
A market valued at roughly $5.9 billion today is projected to grow at over 15% annually through 2034, forcing biomanufacturers to solve process, quality, and scale-up challenges that traditional small-molecule facilities were never built for.
AI is compressing timelines that used to take years.
AI-driven drug discovery has already shortened preclinical trial timelines from years to months in production use cases, and by 2027 AI is expected to be embedded across the full development lifecycle, from target identification to clinical trial optimization.
Data volume is outpacing the ability to use it well.
More than 80% of life sciences executives believe data and digital technologies are critical to future success, yet fragmented systems and inconsistent data standards across clinical, manufacturing, and real-world evidence programs remain the norm rather than the exception.
For organizations without process, quality, and data engineering bench strength, 2027 will separate companies that used this window to modernize biomanufacturing and R&D infrastructure from those still running digital transformations that never reach adoption.
Three forces — trade policy, industrialized delivery, and capital reallocation toward energy and data infrastructure — are converging to reset how engineering, construction, and building materials firms compete.
Tariffs have permanently changed procurement math.
Steel and aluminum tariffs have pushed effective rates on construction goods to their highest levels in four decades, and firms that once treated material cost as a planning constant are now building tariff-adjustment clauses, indexed pricing, and multi-supplier sourcing directly into contracts and estimating models.
Capital is following data centers and energy, not just square footage.
Investment in structures is turning from decline to modest growth heading into 2026 and 2027, with AI-driven data center buildouts and grid, renewable, and industrial policy programs — the CHIPS Act and Infrastructure Investment and Jobs Act among them — absorbing a growing share of new project starts.
Industrialized construction is moving from pilot to standard practice.
Prefabrication, modular assembly, and digital supply-chain “control towers” are becoming the default answer to a persistent skilled-labor shortage, with modular delivery for offices and data centers alone projected to grow faster than traditional construction methods through the decade.
Building materials are being re-specified around embodied carbon.
Low-carbon cement, engineered wood, recycled aggregates, and advanced composites are shifting from differentiators to baseline requirements on projects governed by green building certification and public-sector procurement standards.
For firms without in-house bench strength to plan around these shifts, 2027 will separate organizations that treat volatility as a design constraint from those still pricing projects as if 2019 conditions will return.
One embedded model. Two very different starting points.
Four pressures every life sciences organization is planning around right now.
Embedded engineering and consulting from discovery through commercial supply.
Arrow Ways places engineers and technical professionals directly inside your teams — under your quality systems and your name — while advising on the process and data architecture decisions that determine whether scale-up holds up under regulatory scrutiny.
Embedded process and manufacturing engineers who design and scale GMP-compliant production for biologics, cell, and gene therapies.
Quality and regulatory affairs engineers embedded to build compliant documentation, CAPA systems, and submission-ready processes.
Data engineers and informaticists who unify clinical trial, manufacturing, and real-world evidence data into a usable, auditable foundation.
Automation and facilities engineers supporting flexible cleanroom design, single-use systems, and control system integration for scale-up.
Consulting on supply chain digitization, manufacturing flexibility, and technology adoption strategy built for durable, everyday use.
Your team, not a headcount line.
Arrow Ways doesn’t hand off a resume and disappear. Our engineers and technical professionals work inside your org chart, under your quality and safety standards, reporting to your plant and product leads — with Arrow Ways managing recruiting, compliance, and performance behind the scenes.
That structure lets packaging and paper manufacturers flex specialized technical capacity up or down with capital projects and material conversion timelines, without carrying the fixed overhead of a full internal bench.